These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 19298381

  • 21. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme.
    Oldenburg J, Windyga J, Hampton K, Lalezari S, Tseneklidou-Stoeter D, Beckmann H, Maas Enriquez M.
    Haemophilia; 2016 May; 22(3):349-53. PubMed ID: 26931631
    [Abstract] [Full Text] [Related]

  • 22. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.
    Abshire TC, Brackmann HH, Scharrer I, Hoots K, Gazengel C, Powell JS, Gorina E, Kellermann E, Vosburgh E.
    Thromb Haemost; 2000 Jun; 83(6):811-6. PubMed ID: 10896230
    [Abstract] [Full Text] [Related]

  • 23. Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue.
    Di Minno G, Cerbone AM, Coppola A, Cimino E, Di Capua M, Pamparana F, Tufano A, Di Minno MN.
    Haemophilia; 2010 Jan; 16 Suppl 1():2-6. PubMed ID: 20059562
    [Abstract] [Full Text] [Related]

  • 24. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.
    Strauss T, Lubetsky A, Ravid B, Bashari D, Luboshitz J, Lalezari S, Misgav M, Martinowitz U, Kenet G.
    Haemophilia; 2011 Jul; 17(4):625-9. PubMed ID: 21299743
    [Abstract] [Full Text] [Related]

  • 25. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation.
    Kreuz W, Gill JC, Rothschild C, Manco-Johnson MJ, Lusher JM, Kellermann E, Gorina E, Larson PJ, International Kogenate-FS Study Group.
    Thromb Haemost; 2005 Mar; 93(3):457-67. PubMed ID: 15735795
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela.
    Boadas A, Fernández-Palazzi F, De Bosch NB, Cedeño M, Ruiz-Sáez A.
    Haemophilia; 2011 May; 17(3):422-7. PubMed ID: 21118333
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Continuous infusion of factor VIII for surgery and major bleeding.
    Hay CR, Doughty HI, Savidge GF.
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S15-9. PubMed ID: 8735792
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
    Kulkarni R, Karim FA, Glamocanin S, Janic D, Vdovin V, Ozelo M, Rageliene L, Carboni E, Laguna P, Dobaczewski G, Seremetis S, Lindblom A, Santagostino E.
    Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.
    Hampton K, Chowdary P, Dunkley S, Ehrenforth S, Jacobsen L, Neff A, Santagostino E, Sathar J, Takedani H, Takemoto CM, Négrier C.
    Haemophilia; 2017 Sep; 23(5):689-696. PubMed ID: 28470862
    [Abstract] [Full Text] [Related]

  • 39. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E.
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.